 "Aurobindo Pharma wrests second position among drug firms from Lupin")
Shares of Aurobindo Pharma gained 5 per cent to Rs 538 on the BSE on Friday after the company’s operational revenues witnessed a strong growth of 11.9 per cent year-on-year (YoY) at Rs 5,895 crore in December quarter (Q3FY20). US revenue for Q3FY20 witnessed a growth of 22 per cent YoY to Rs 2,969 crore, accounting for 50.4 per cent of consolidated revenue.
The stock of the drug company was trading higher for the fifth straight day, up 14 per cent, against a 4 per cent rise in the S&P BSE Sensex during the period.
The company’s consolidated
The stock of the drug company was trading higher for the fifth straight day, up 14 per cent, against a 4 per cent rise in the S&P BSE Sensex during the period.
The company’s consolidated
